Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 6.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 127,500 shares of the company’s stock after acquiring an additional 7,800 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Teva Pharmaceutical Industries Limited were worth $2,244,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. San Francisco Sentry Investment Group CA acquired a new position in shares of Teva Pharmaceutical Industries Limited during the second quarter valued at about $106,000. Kistler Tiffany Companies LLC raised its position in shares of Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after buying an additional 1,571 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its position in shares of Teva Pharmaceutical Industries Limited by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after buying an additional 94 shares during the last quarter. Penserra Capital Management LLC bought a new stake in Teva Pharmaceutical Industries Limited in the third quarter valued at about $129,000. Finally, Cutler Capital Management LLC bought a new stake in Teva Pharmaceutical Industries Limited in the second quarter valued at about $133,000. 56.45% of the stock is owned by hedge funds and other institutional investors.

A number of research firms recently weighed in on TEVA. Jefferies Group LLC reissued a “hold” rating and issued a $26.00 target price (down previously from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Deutsche Bank AG reissued a “buy” rating and issued a $28.00 target price (down previously from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Susquehanna Bancshares Inc decreased their price objective on shares of Teva Pharmaceutical Industries Limited from $20.00 to $14.00 and set a “positive” rating on the stock in a research note on Monday, November 6th. Sanford C. Bernstein cut shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $42.00 to $28.00 in a research note on Friday, August 4th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price objective (down from $31.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Six analysts have rated the stock with a sell rating, eighteen have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $23.26.

Shares of Teva Pharmaceutical Industries Limited (TEVA) opened at $11.78 on Friday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The stock has a market cap of $12,039.60, a PE ratio of 2.74 and a beta of 0.52. Teva Pharmaceutical Industries Limited has a 12 month low of $10.85 and a 12 month high of $41.19.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a $0.085 dividend. This represents a $0.34 annualized dividend and a yield of 2.89%. The ex-dividend date of this dividend is Monday, November 27th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is -15.80%.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Shares Bought by Mitsubishi UFJ Kokusai Asset Management Co. Ltd.” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/11/11/teva-pharmaceutical-industries-limited-teva-shares-bought-by-mitsubishi-ufj-kokusai-asset-management-co-ltd.html.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Limited (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.